Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Showcase Companies

Stockhouse is proud to showcase a portfolio of companies that we are watching closely. Learn more about these companies as part of your own investment research. Consider using the tools below to be first in line for important news and updates. view all showcase companies

Cardiol Therapeutics Inc. T.CRDL

Cardiol Therapeutics’ lead product, CardiolRx™, is an oral pharmaceutical that is currently being evaluated in the Phase II multi-national ARCHER trial in patients presenting with acute myocarditis. Cardiol has received IND authorization from the FDA to conduct a clinical study to evaluate CardiolRx™ in a Phase II multi-center open-label pilot study in recurrent pericarditis. Cardiol is developing a subcutaneously administered drug formulation of cannabidiol intended for use in heart failure.

Latest News

Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement


CardiolRx study demonstrates ‘protective effects’ vs. acute pericarditis


Cardiol Therapeutics (TSX:CRDL) discovers protective effects of CardiolRX


Cardiol Therapeutics Announces Study Results Demonstrating Protective Effects of CardiolRx(TM) in...


Cardiol Therapeutics Prioritizes Phase II Clinical Programs in Underserved Heart Diseases


Cardiol Therapeutics (TSX: CRDL) announces CardiolRx pre-clinical study results


Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx(TM) Inhibits...


Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart...


60+ Companies to Present at the 2nd Annual MicroCap Rodeo - Windy City Roundup Conference on...


Is this company the next GW Pharma? Phase II study now underway


Cardiol Therapeutics (TSX:CRDL) reports first patient enrolled in Phase Il clinical trial for...


Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of...


A medical play developing CBD-based treatments for cardiovascular diseases


Cardiol Therapeutics Reports Results of 2022 Annual General Meeting


Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 P.M. EDT